Latest News and Press Releases

ANKARA, Turkey, Nov. 20, 2022 (GLOBE NEWSWIRE) -- Digital health start-up H2o therapeutics received 510(k) marketing clearance from the U.S. Food and Drug Administration for its prescription mobile...

Dublin, Feb. 17, 2022 (GLOBE NEWSWIRE) -- The "Neurorehabilitation Market by Type, Application, and End-User: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to...

Herantis Pharma Oyj:n suunnattu osakeanti on ylimerkitty moninkertaisesti ja toteutetaan suunnitellusti Herantis Pharma Oyj Yhtiötiedote 2.12.2019 kello 20:00 TÄMÄN TIEDOTTEEN SISÄLTÄMÄ TIETO EI...

Herantis Pharma Plc's directed share issue is oversubscribed multiple times and completed as planned Herantis Pharma Plc Company release 2 December 2019 at 8:00 pm THE INFORMATION CONTAINED IN...

Herantis Pharma Oyj päivittää käynnissä olevan Vaiheen 1-2 CDNF-tutkimuksen aikataulua Herantis Pharma Oyj Yhtiötiedote 26.9.2019 kello 9:00 Herantis Pharma Oyj (“Herantis” tai “Yhtiö”) tiedotti...

Herantis Pharma Plc Provides Update on Timeline for Ongoing Phase 1-2 CDNF Trial Herantis Pharma Plc Company release 26 September 2019 at 9:00 AM Herantis Pharma Plc (“Herantis” or “Company”)...

Herantis Pharma Oyj tiedottaa onnistuneesta noin 5,8 miljoonan euron suunnatusta osakeannista   Herantis Pharma Oyj Yhtiötiedote 12.3.2019 kello 17:00 Ei julkistettavaksi tai levitettäväksi, suoraan...

Herantis Pharma Plc Announces Positive Outcome of Directed Share Issue Raising EUR 5.8 Million Herantis Pharma Plc Company release 12 March 2019, 5:00 pm Not for publication or distribution,...

CLARKSVILLE, MD--(Marketwired - January 24, 2017) - Neuronascent's U.S. Patent No. 9,539,261, which issued on January 10, 2017, claims methods of stimulating neurogenesis and/or inhibiting neuronal...

MIAMI, Nov. 14, 2011 (GLOBE NEWSWIRE) -- Founded in California in 2008, Amarantus Biosciences, Inc. (OTCBB:AMBS) is now poised to take the biotech world by storm with their proprietary new technology....